Mixed bag for sure.
DLT which limits the dose increase, but the positive is cumulatively the dosage is still the same ie 8x6 vs 12v4.
another CR, albeit at 2 X 12.
going into pretaxane is great, as it allows the potential for P3 to be earlier stage cohorts. This will mean a larger piece of the pie when things eventuate(a long road ahead, but important for potential suitors to determine revenue).
pretaxane 46% over 80% reduction in PSA, with 30% dosed at 4-8GBq and the remaining dosed at 12-24GBq. Hopefully when this is dosed at RP2D(48GBq), we will see better responses.
Mixed bag for sure.DLT which limits the dose increase, but the...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.39 |
Change
0.300(14.4%) |
Mkt cap ! $768.3M | |||
| Open | High | Low | Value | Volume |
| $2.09 | $2.40 | $2.07 | $8.519M | 3.760M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | $2.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.39 | 4380 | 2 |
View Market Depth
| Last trade - 16.21pm 26/06/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |